✦ LIBER ✦

Appendicitis among liver transplant recipients

✍ Scribed by Peter L. Abt; Ibrahim Abdullah; Kathleen Korenda; Adam Frank; Heather Peterman; G. Robert Stephenson; James F. Markmann; Abraham Shaked; Kim M. Olthoff

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 60 KB
Volume: 11
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.20568

No coin nor oath required. For personal study only.

✦ Synopsis

Appendicitis among liver transplant recipients has not been described in the current literature. We report 8 recipients who experienced appendicitis three weeks to 181 months after liver transplantation (LT). Initial presenting findings differed from the nonimmunosuppressed population in that a majority of the patients did not have leukocytosis (>10,000 cells/mm3). Four patients experienced perforation, three of whom presented three days after the development of abdominal pain. All patients recovered after surgery without untoward sequela.

📜 SIMILAR VOLUMES

Visceral leishmaniasis among liver trans

Visceral leishmaniasis among liver transplant recipients: An overview

✍ Isabel Campos-Varela; Oscar Len; Lluís Castells; Natalia Tallada; Esteban Ribera 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

There has been an increase in the incidence of visceral leishmaniasis (VL), especially among hemopoietic and renal transplant recipients. [1][2][3] Remarkably, very few cases have been described among liver transplant recipients. We report a case of VL in a liver transplant recipient and analyze the

Probabilities of relapse and abstinence

Probabilities of relapse and abstinence among liver transplant recipients

✍ Thomas P. Beresford 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Andrea DiMartini and her colleagues have provided prospectively gathered data on the course of alcohol use among liver transplant recipients during the first 5 years of postgraft living. Having worked with the difficult issue of alcohol use disorders and liver transplantation for a number of years n

Survival among pediatric liver transplan

Survival among pediatric liver transplant recipients: Impact of segmental grafts

✍ Peter L. Abt; Rachel Rapaport-Kelz; Niraj M. Desai; Adam Frank; Seema Sonnad; El 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Segmental liver transplantation with living donor (LD), reduced cadaveric (Reduced), and split cadaveric (Split) allografts has expanded the availability of size-appropriate organs for pediatric recipients. The relevance of recipient age to the selection of graft type has not been fully explored, bu

Adherence in liver transplant recipients

✍ Patrizia Burra; Giacomo Germani; Francesca Gnoato; Silvia Lazzaro; Francesco Pao 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Adherence to a medical regimen has been defined as the extent to which a patient's behavior coincides with clinical prescriptions. In liver transplant patients, adherence to immunosuppressive therapy and to medical indications in general is crucial for short-and long-term outcomes. Nonadherence to i

Antifungal prophylaxis in liver transpla

Antifungal prophylaxis in liver transplant recipients

✍ Gregory A. Eschenauer; Simon W. Lam; Peggy L. Carver 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

Although the overall incidence of fungal infections in liver transplant recipients has declined, these infections still contribute significantly to the morbidity and mortality of patients with risk factors for infection. Although antifungal prophylaxis has been widely studied and practiced, no conse

Hepatitis B in liver transplant recipien

Hepatitis B in liver transplant recipients

✍ Robert G. Gish; Timothy McCashland 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

1. The use of low-dose immunosuppressive therapy along with pre- and posttransplantation nucleos(t)ide therapy and posttransplantation hepatitis B immunoglobulin (HBIG) has yielded marked improvements in survival. 2. Lamivudine (Epivir-HBV), adefovir (Hepsera), entecavir (Baraclude), tenofovir (Vire